(Q50661031)

17 March 2018

title

Soluble betaglycan reduces renal damage progression in db/db mice. (English)

1 reference

17 March 2018

author name string

Patricia Juárez

1

1 reference

17 March 2018

M Magdalena Vilchis-Landeros

2

1 reference

17 March 2018

José Ponce-Coria

3

1 reference

17 March 2018

Valentín Mendoza

4

1 reference

17 March 2018

Rogelio Hernández-Pando

5

1 reference

17 March 2018

Norma A Bobadilla

6

1 reference

17 March 2018

Fernando López-Casillas

7

1 reference

17 March 2018

publication date

5 September 2006

1 reference

17 March 2018

American Journal of Physiology - Renal Physiology

published in

1 reference

17 March 2018

volume

292

1 reference

17 March 2018

page(s)

F321-9

1 reference

17 March 2018

issue

1

1 reference

17 March 2018

TGF-beta receptors and actions

cites work

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00264.2006

Role of transforming growth factor beta in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00264.2006

Nephron number and renal risk in hypertension and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00264.2006

Increased urinary type IV collagen marks the development of glomerular pathology in diabetic d/db mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00264.2006

Prevention of diabetic nephropathy in db/db mice with glycated albumin antagonists. A novel treatment strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00264.2006

Activation of renal signaling pathways in db/db mice with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00264.2006

Increased glomerular and tubular expression of transforming growth factor-beta1, its type II receptor, and activation of the Smad signaling pathway in the db/db mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00264.2006

The TGF-beta superfamily: new members, new receptors, and new genetic tests of function in different organisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00264.2006

Deranged transcriptional regulation of cell-volume-sensitive kinase hSGK in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00264.2006

Betaglycan can act as a dual modulator of TGF-beta access to signaling receptors: mapping of ligand binding and GAG attachment sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00264.2006

Betaglycan presents ligand to the TGF beta signaling receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00264.2006

The transforming growth factor-beta family

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00264.2006

TGFbeta signaling in growth control, cancer, and heritable disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00264.2006

Minimal effects on immune parameters following chronic anti-TGF-beta monoclonal antibody administration to normal mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00264.2006

The podocyte's response to injury: role in proteinuria and glomerulosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00264.2006

Diabetic kidney disease in thedb/dbmouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00264.2006

Heart and liver defects and reduced transforming growth factor beta2 sensitivity in transforming growth factor beta type III receptor-deficient embryos

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00264.2006

SMP-534 ameliorates progression of glomerular fibrosis and urinary albumin in diabetic db/db mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00264.2006

The shedding of betaglycan is regulated by pervanadate and mediated by membrane type matrix metalloprotease-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00264.2006

Transforming growth factor-beta and Smad signalling in kidney diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00264.2006

Identification of distinct inhibin and transforming growth factor beta-binding sites on betaglycan: functional separation of betaglycan co-receptor actions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00264.2006

TGF-beta isoforms in renal fibrogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00264.2006

Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00264.2006

Role of the Juxtamembrane Domains of the Transforming Growth Factor-α Precursor and the β-Amyloid Precursor Protein in Regulated Ectodomain Shedding

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00264.2006

Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00264.2006

10.1152/AJPRENAL.00264.2006

21 January 2018

Identifiers

DOI

1 reference

17 March 2018

release_ke574dwyfvgl3flcpvenaw2phi

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ke574dwyfvgl3flcpvenaw2phi

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

16954341

1 reference

17 March 2018